Physician profile
Rajeev Dhupar
NPI 1750559761
$64,725.54
in general payments reported to CMS, 2019-2025
15 companies · $24K in 2025
The $24K reported for 2025 was more than what 95% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $184 · 2021: $945 · 2022: $15K · 2023: $16K · 2024: $7,884 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Honoraria: $7,750 · Education: $7,750 · Travel and Lodging: $3,823 · Food and Beverage: $3,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,833.33 |
| Honoraria | $7,750.00 |
| Education | $7,750.00 |
| Travel and Lodging | $3,823.07 |
| Food and Beverage | $3,236.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elucent Medical | $52,208.10 | 2022-2025 | |
| Intuitive Surgical, INC. | $9,633.31 | 2023-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,063.78 | 2021-2024 | |
| Ethicon INC. | $537.27 | 2020-2023 | Monarch Platform |
| Becton, Dickinson and Company | $433.33 | 2023 | |
| Davol INC. | $138.59 | 2023 | Progel Applicator Spray Tips |
| Pinnacle Biologics, INC | $115.92 | 2021-2022 | |
| On Target Laboratories, INC | $104.04 | 2025 | Cytalux |
| E.R. Squibb & Sons, L.L.C. | $93.26 | 2023 | Opdivo |
| Ethicon US, LLC | $92.67 | 2023 | Ethicon, Vistaseal, Surgicel Nu-Knit |
| Medtronic, INC. | $91.71 | 2022 | |
| Edwards Lifesciences Corporation | $82.63 | 2025 | Inspiris Resilia Aortic Valve |
| Abbott Laboratories | $72.63 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Galvanize Therapeutics, INC | $58.30 | 2023 | Aliya System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Dhupar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.